Towa Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
Towa Pharmaceutical has a total shareholder equity of ¥163.0B and total debt of ¥213.1B, which brings its debt-to-equity ratio to 130.8%. Its total assets and total liabilities are ¥451.2B and ¥288.2B respectively. Towa Pharmaceutical's EBIT is ¥19.2B making its interest coverage ratio 20.7. It has cash and short-term investments of ¥35.0B.
Anahtar bilgiler
130.8%
Borç/özkaynak oranı
JP¥213.12b
Borç
| Faiz karşılama oranı | 20.7x |
| Nakit | JP¥35.04b |
| Eşitlik | JP¥162.99b |
| Toplam yükümlülükler | JP¥288.24b |
| Toplam varlıklar | JP¥451.23b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 4553's short term assets (¥234.8B) exceed its short term liabilities (¥80.0B).
Uzun Vadeli Yükümlülükler: 4553's short term assets (¥234.8B) exceed its long term liabilities (¥208.2B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 4553's net debt to equity ratio (109.3%) is considered high.
Borcun Azaltılması: 4553's debt to equity ratio has increased from 68.4% to 130.8% over the past 5 years.
Borç Kapsamı: 4553's debt is not well covered by operating cash flow (5%).
Faiz Kapsamı: 4553's interest payments on its debt are well covered by EBIT (20.7x coverage).